Stereotactic body radiation therapy: Scope of the literature

Annals of Internal Medicine

Volumn 154, Issue 11, 2011, Pages 737-745

  Tipton, Kelley ^a   Launders, Jason H ^a   Inamdar, Rohit ^a   Miyamoto, Curtis ^b   Schoelles, Karen ^a  

^a ECRI INSTITUTE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INFORMATION RETRIEVAL; NEOPLASM; PRIORITY JOURNAL; PUBLISHING; RADIATION SAFETY; REVIEW; SOLID TUMOR; STEREOTACTIC BODY RADIATION THERAPY;

EID: 79958143525     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-11-201106070-00343     Document Type: Review

References (141)

1. Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. 2005;55:117-34. [PMID: 15761080]
2. American Hospital Association. AHA Guide to the Health Care Field 2009 Edition. Chicago: American Hosp Assoc; 2008.
3. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol. 2010. [PMID: 20805737]
4. Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, et al. Stereotactic Body Radiation Therapy. Technical Brief no. 6. (Prepared by ECRI Institute Evidence-based Practice Center under Contract no. HHSA-290-02-0019.) AHRQ Publication no. 10 (11)-EHC058-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2011. Available at www.effectivehealthcare.ahrq.gov/reports/final.cfm.
5. Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75:71-5. [PMID: 19250766]
6. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74:47-54. [PMID: 18977095]
7. Haasbeek CJ, Lagerwaard FJ, de Jaeger K, Slotman BJ, Senan S. Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer. 2009;115:587-94. [PMID: 19130457]
8. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585-91. [PMID: 19255313]
9. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curativeintent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010;33:157-63. [PMID: 19770627]
10. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol. 2009;4:838-44. [PMID: 19487961]
11. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685-92. [PMID: 18164849]
12. Aoki M, Abe Y, Kondo H, Hatayama Y, Kawaguchi H, Fujimori A, et al. Clinical outcome of stereotactic body radiotherapy of 54 Gy in nine fractions for patients with localized lung tumor using a custom-made immobilization system. Radiat Med. 2007;25:289-94. [PMID: 17634882]
13. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45:856-64. [PMID: 16982550]
14. Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007;85:435-42. [PMID: 18053602]
15. Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, et al. Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol. 2008;87:418-24. [PMID: 18439693]
16. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26:657-64. [PMID: 18172187]
17. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I nonsmall cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001; 51:666-70. [PMID: 11597807]
18. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117-25. [PMID: 16765528]
19. Gunvén P, Blomgren H, Lax I. Radiosurgery for recurring liver metastases after hepatectomy. Hepatogastroenterology. 2003;50:1201-4. [PMID: 14571698]
20. Sinha B, McGarry RC. Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. Int J Radiat Oncol Biol Phys. 2006;66:1120-4. [PMID: 17145532]
21. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787-95. [PMID: 16982541]
22. Teh BS, Paulino AC, Lu HH, Chiu JK, Richardson S, Chiang S, et al. Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites. Technol Cancer Res Treat. 2007;6:347-54. [PMID: 17668943]
23. Brown WT, Wu X, Wen BC, Fowler JF, Fayad F, Amendola BE, et al. Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors. Comput Aided Surg. 2007;12:253-61. [PMID: 17957532]
24. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72:398-403. [PMID: 18374506]
25. Kunos C, von Gruenigen V, Waggoner S, Brindle J, Zhang Y, Myers B, et al. Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy. Technol Cancer Res Treat. 2008;7:375-80. [PMID: 18783287]
26. Kim MS, Choi C, Yoo S, Cho C, Seo Y, Ji Y, et al. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. Jpn J Clin Oncol. 2008;38:695-700. [PMID: 18723850]
27. Jereczek-Fossa BA, Kowalczyk A, D'Onofrio A, Catalano G, Garibaldi C, Boboc G, et al. Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients. Strahlenther Onkol. 2008;184:36-40. [PMID: 18188521]
28. Fritz P, Kraus HJ, Blaschke T, Mühlnickel W, Strauch K, Engel-Riedel W, et al. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer. 2008;60:193-9. [PMID: 18045732]
29. Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/ computed tomography-based treatment planning. Clin Lung Cancer. 2008;9: 217-21. [PMID: 18650169]
30. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008;8:351. [PMID: 19038025]
31. Casamassima F, Masi L, Bonucci I, Polli C, Menichelli C, Gulisano M, et al. Relevance of biologically equivalent dose values in outcome evaluation of stereotactic radiotherapy for lung nodules. Int J Radiat Oncol Biol Phys. 2008; 71:145-51. [PMID: 18164855]
32. Pennathur A, Luketich JD, Heron DE, Abbas G, Burton S, Chen M, et al. Stereotactic radiosurgery for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg. 2009;137:597-604. [PMID: 19258073]
33. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73: 112-8. [PMID: 18786780]
34. Choi CW, Cho CK, Yoo SY, Kim MS, Yang KM, Yoo HJ, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys. 2009;74:147-53. [PMID: 18990511]
35. Ahn SH, Han MS, Yoon JH, Jeon SY, Kim CH, Yoo HJ, et al. Treatment of stage I non-small cell lung cancer with CyberKnife, image-guided robotic stereotactic radiosurgery. Oncol Rep. 2009;21:693-6. [PMID: 19212628]
36. Nakagawa K, Aoki Y, Tago M, Terahara A, Ohtomo K. Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors: original research in the treatment of thoracic neoplasms. Int J Radiat Oncol Biol Phys. 2000;48:449-57. [PMID: 10974461]
37. Harada T, Shirato H, Ogura S, Oizumi S, Yamazaki K, Shimizu S, et al. Real-time tumor-tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy. Cancer. 2002;95:1720-7. [PMID: 12365020]
38. Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM Jr, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 2003;75:1097-101. [PMID: 12683544]
39. Lee SW, Choi EK, Park HJ, Ahn SD, Kim JH, Kim KJ, et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer. 2003;40:309-15. [PMID: 12781430]
40. Onishi H, Kuriyama K, Komiyama T, Tanaka S, Sano N, Marino K, et al. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer. 2004;45:45-55. [PMID: 15196734]
41. Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, et al. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med. 2004;18:669-74. [PMID: 15682847]
42. Song DY, Benedict SH, Cardinale RM, Chung TD, Chang MG, Schmidt-Ullrich RK. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol. 2005;28:591-6. [PMID: 16317270]
43. Shioyama Y, Nakamura K, Anai S, Sasaki T, Ooga S, Saku M, et al. Stereotactic radiotherapy for lung and liver tumors using a body cast system: setup accuracy and preliminary clinical outcome. Radiat Med. 2005;23:407-13. [PMID: 16389982]
44. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48-53. [PMID: 15990186]
45. Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45:796-801. [PMID: 16982542]
46. Yoon SM, Choi EK, Lee SW, Yi BY, Ahn SD, Shin SS, et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors. Acta Oncol. 2006;45:1108-14. [PMID: 17118847]
47. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833-9. [PMID: 17050868]
48. Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870-5. [PMID: 16982552]
49. Nuyttens JJ, Prévost JB, Praag J, Hoogeman M, Van Klaveren RJ, Levendag PC, et al. Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: marker placement and early results. Acta Oncol. 2006;45: 961-5. [PMID: 16982564]
50. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1:802-9. [PMID: 17409963]
51. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823-30. [PMID: 16982546]
52. Hodge W, Tom WA, Jaradat HA, Orton NP, Khuntia D, Traynor A, et al. Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta Oncol. 2006;45:890-6. [PMID: 16982555]
53. Ricardi U, Guarneri A, Mantovani C, Ciammella P, Giglioli FR, Ragona R. Stereotactic body radiation therapy for early non-small cell lung cancer: experience at the University of Turin. J Thorac Oncol. 2007;2:S47. [PMID: 17457235]
54. Ponsky LE, Mahadevan A, Gill IS, Djemil T, Novick AC. Renal radiosurgery: initial clinical experience with histological evaluation. Surg Innov. 2007;14: 265-9. [PMID: 18178914]
55. Salazar OM, Sandhu TS, Lattin PB, Chang JH, Lee CK, Groshko GA, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2008;72:707-15. [PMID: 18455322]
56. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:967-71. [PMID: 18954709]
57. Kopek N, Paludan M, Petersen J, Hansen AT, Grau C, Høyer M. Comorbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol. 2009;93:402-7. [PMID: 19559492]
58. Collins BT, Vahdat S, Erickson K, Collins SP, Suy S, Yu X, et al. Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol. 2009;2:1. [PMID: 19149899]
59. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-6. [PMID: 20233825]
60. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010; 17:2092-101. [PMID: 20224860]
61. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:796-801. [PMID: 19427740]
62. Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010;140:377-86. [PMID: 20400121]
63. Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat. 2010;9:479-87. [PMID: 20815419]
64. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12:218-25. [PMID: 20231127]
65. Shin YJ, Kim MS, Yoo SY, Cho CK, Seo YS, Kang JK, et al. Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori. 2010;96:65-70. [PMID: 20437860]
66. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136: 625-30. [PMID: 19882171]
67. Kim JH, Kim MS, Yoo SY, Lim SM, Lee GH, Yi KH. Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer. Otolaryngol Head Neck Surg. 2010;142:338-43. [PMID: 20172377]
68. Kang JK, Kim MS, Kim JH, Yoo SY, Cho CK, Yang KM, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27:273-8. [PMID: 20373133]
69. Kopek N, Holt MI, Hansen AT, Høyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2010;94:47-52. [PMID: 19963295]
70. Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, et al. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. J Hematol Oncol. 2010;3:6. [PMID: 20132557]
71. Kim MS, Yoo SY, Cho CK, Yoo HJ, Choi CW, Seo YS, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology. 2009;76:212-9. [PMID: 19218825]
72. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572-8. [PMID: 19255321]
73. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579-84. [PMID: 19255320]
74. van der Voort van Zyp NC, Prévost JB, Hoogeman MS, Praag J, van der Holt B, Levendag PC, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009; 91:296-300. [PMID: 19297048]
75. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72:678-86. [PMID: 18395362]
76. Hof H, Hoess A, Oetzel D, Debus J, Herfarth K. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol. 2007;183:673-8. [PMID: 18040611]
77. Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer. 2007;110:148-55. [PMID: 17516437]
78. Nuyttens JJ, Prevost JB, Van der Voort van Zijp NC, Hoogeman M, Levendag PC. Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity. Technol Cancer Res Treat. 2007;6:605-10. [PMID: 17994790]
79. Ernst-Stecken A, Lambrecht U, Mueller R, Sauer R, Grabenbauer G. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study. Strahlenther Onkol. 2006;182: 696-702. [PMID: 17149575]
80. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol. 2006;45: 831-7. [PMID: 16982547]
81. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838-47. [PMID: 16982548]
82. Wulf J, Hädinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177:645-55. [PMID: 11789403]
83. Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78:735-42. [PMID: 20171803]
84. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115:665-72. [PMID: 19117351]
85. Milano MT, Chen Y, Katz AW, Philip A, Schell MC, Okunieff P. Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol. 2009;91:301-6. [PMID: 19329210]
86. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, et al. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol. 2009;4:976-82. [PMID: 19633473]
87. Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 2009;66:89-93. [PMID: 19168260]
88. Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys. 2009;73:442-8. [PMID: 18990507]
89. Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I nonsmall cell lung cancer-a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359-67. [PMID: 18768228]
90. Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:374-81. [PMID: 18029106]
91. Svedman C, Karlsson K, Rutkowska E, Sandström P, Blomgren H, Lax I, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;47:1578-83. [PMID: 18607859]
92. Joyner M, Salter BJ, Papanikolaou N, Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol. 2006;45:802-7. [PMID: 16982543]
93. Hamamoto Y, Kataoka M, Yamashita M, Shinkai T, Kubo Y, Sugawara Y, et al. Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer. Jpn J Clin Oncol. 2010;40: 125-9. [PMID: 19825814]
94. Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2010;77:1146-50. [PMID: 19800181]
95. Unger K, Ju A, Oermann E, Suy S, Yu X, Vahdat S, et al. CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 2010;3:39. [PMID: 20969774]
96. Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer. 2010;69:77-85. [PMID: 19910075]
97. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer. 2010;46:1026-32. [PMID: 20153959]
98. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486-93. [PMID: 20350791]
99. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A. Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol. 2010;17:2877-83. [PMID: 20574773]
100. Jorcano S, Molla M, Escude L, Sanz S, Hidalgo A, Toscas JI, et al. Hypofractionated extracranial stereotactic radiotherapy boost for gynecologic tumors: a promising alternative to high-dose rate brachytherapy. Technol Cancer Res Treat. 2010;9:509-14. [PMID: 20815422]
101. Guckenberger M, Bachmann J, Wulf J, Mueller G, Krieger T, Baier K, et al. Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiother Oncol. 2010;94:53-9. [PMID: 20079550]
102. Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys. 2009;73:832-7. [PMID: 18760543]
103. Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429-34. [PMID: 18022720]
104. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28:928-35. [PMID: 20065181]
105. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol. 2010;102:209-14. [PMID: 20740576]
106. Townsend NC, Huth BJ, Ding W, Garber B, Mooreville M, Arrigo S, et al. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. 2011;34:6-10. [PMID: 20065849]
107. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78:1073-80. [PMID: 20207492]
108. Moll M, Escude L, Nouet P, Popowski Y, Hidalgo A, Rouzaud M, et al. Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys. 2005;62:118-24. [PMID: 15850911]
109. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043-8. [PMID: 18755555]
110. Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010;5:32. [PMID: 20459699]
111. Takeda A, Ohashi T, Kunieda E, Enomoto T, Sanuki N, Takeda T, et al. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys. 2010;77:685-90. [PMID: 20510193]
112. Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat. 2010;9:473-7. [PMID: 20815418]
113. Oermann EK, Slack RS, Hanscom HN, Lei S, Suy S, Park HU, et al. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediateto high-risk prostate cancer. Technol Cancer Res Treat. 2010;9:453-62. [PMID: 20815416]
114. Aluwini S, van Rooij P, Hoogeman M, Bangma C, Kirkels WJ, Incrocci L, et al. CyberKnife stereotactic radiotherapy as monotherapy for low-to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol. 2010;24:865-9. [PMID: 20433370]
115. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011;6:3. [PMID: 21219625]
116. Meyer JL, Verhey L, Xia P, Wong J. New technologies in the radiotherapy clinic. Front Radiat Ther Oncol. 2007;40:1-17. [PMID: 17641499]
117. MEDCAC Meeting: Radiation Therapy for Localized Prostate Cancer. Baltimore, MD: Centers for Medicare & Medicaid Services; 21 April 2010. Accessed at www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?&bc_BAAAAAAAAAAA&MEDCACId_54& on 15 March 2011.
118. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev. 2008;34:719-27. [PMID: 18657910]
119. Brock J, Ashley S, Bedford J, Nioutsikou E, Partridge M, Brada M. Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol (R Coll Radiol). 2008;20:666-76. [PMID: 18676130]
120. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1-11. [PMID: 20074823]
121. Calcerrada Díaz-Santos N, Blasco Amaro JA, Cardiel GA, Andradas Aragonés E. The safety and efficacy of robotic image-guided radiosurgery system treatment for intra-and extracranial lesions: a systematic review of the literature. Radiother Oncol. 2008;89:245-53. [PMID: 18760852]
122. Khrizman P, Small W Jr, Dawson L, Benson AB 3rd. The use of stereotactic body radiation therapy in gastrointestinal malignancies in locally advanced and metastatic settings. Clin Colorectal Cancer. 2010;9:136-43. [PMID: 20643617]
123. Sawrie SM, Fiveash JB, Caudell JJ. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control. 2010;17:111-9. [PMID: 20404794]
124. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010;5:1091-9. [PMID: 20479693]
125. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078-101. [PMID: 20879569]
126. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637-44. [PMID: 18091059]
127. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, et al. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1414-24. [PMID: 18990508]
128. Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, Kim JH, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int. 2009;29:147-52. [PMID: 18795897]
129. Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-doseper-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004;27:646-8. [PMID: 15577450]
130. Henderson M, McGarry R, Yiannoutsos C, Fakiris A, Hoopes D, Williams M, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:404-9. [PMID: 18394819]
131. Kawase T, Takeda A, Kunieda E, Kokubo M, Kamikubo Y, Ishibashi R, et al. Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions. Int J Radiat Oncol Biol Phys. 2009;74:349-54. [PMID: 19427551]
132. Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Mantovani C, Fiandra C, et al. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol. 2009;48:571-7. [PMID: 19031164]
133. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48:578-83. [PMID: 19373699]
134. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer. 2007;56:229-34. [PMID: 17353064]
135. Muacevic A, Drexler C, Wowra B, Schweikard A, Schlaefer A, Hoffmann RT, et al. Technical description, phantom accuracy, and clinical feasibility for single-session lung radiosurgery using robotic image-guided real-time respiratory tumor tracking. Technol Cancer Res Treat. 2007;6:321-8. [PMID: 17668940]
136. Paludan M, Traberg Hansen A, Petersen J, Grau C, Høyer M. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: is there a dose-volume dependency? Acta Oncol. 2006;45: 818-22. [PMID: 16982545]
137. Scorsetti M, Navarria P, Facoetti A, Lattuada P, Urso G, Mirandola A, et al. Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. Anticancer Res. 2007;27:3615-9. [PMID: 17972525]
138. Hof H, Zgoda J, Nill S, Hoess A, Kopp-Schneider A, Herfarth K, et al. Time-and dose-dependency of radiographic normal tissue changes of the lung after stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1369-74. [PMID: 19932943]
139. Gerszten PC, Ozhasoglu C, Burton SA, Welch WC, Vogel WJ, Atkins BA, et al. CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. Neurosurg Focus. 2003;15:E7. [PMID: 15350038]
140. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;70:1588-97. [PMID: 18374232]
141. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099-105. [PMID: 17336216]